what jumps out to us at first view is that while the core services of hormone balancing and peptide therapy overlap, they are more focused on the cosmetic side of longevity – such as skin and aesthetics – where we are more focused on the clinical side of longevity – such as helping overcome joint pain and other physical symptomology. We prioritize the clinically-led approach to helping solve symptoms for the whole person (i.e.. their full spectrum of health concerns, not just their hormones) and supporting them in coming off medications for chronic issues (such as diabetes medications etc.). Furthermore, we are considering acquisitions deeper into the medical field, such as through regenerative medicine or via OBGyn clinics, versus focusing increasingly on the cosmetic/aesthetic aspect of ageing.
Of course, we will keep them on our radar due our target demographic likely having overlap and because we may see potential synergies in the future.
Just as an additional point of interest here, we had an investor this week say that they believe that competition is a positive thing in the longevity space as it helps raise overall awareness and market size, reducing the need to spend marketing dollars educating potential customers/patients.
Comments are closed